BACKGROUND:Intracoronary administration of autologous bone marrow stem cells (BMC) has been shown to result in a subtle improvement of global left ventricular ejection fraction after ST-elevation myocardial infarction (STEMI), but the overall benefits of BMC therapy are still unclear. We studied the influence of intracoronary injections of BMC on levels of natriuretic peptides and inflammatory mediators, which are well established prognostic biomarkers, in patients with STEMI. METHODS: In this randomized, double-blind study, consecutive patients with an acute STEMI treated with thrombolysis followed by PCI 2-6 days after STEMI, were randomly assigned to receive either intracoronary BMC or placebo medium into the infarct-related artery. Blood samples were drawn for biochemical determinations. RESULTS: From baseline to 6 months, there was a significant decrease in the levels of N-terminal probrain natriuretic peptide (NT-proBNP), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) in the whole patient population (P < 0.001 for all). However, no difference was observed between the BMC group (n = 39) and the placebo group (n = 39) in the change of the levels of NT-proANP (median -54 vs. +112 pmol/L), NT-proBNP (-88 vs. -115 pmol/L) or inflammatory markers IL-6 (-3.86 vs. -5.61 pg/mL), hsCRP (-20.29 vs. -22.36 mg/L) and tumor necrosis factor α (-0.12 vs. -0.80 pg/mL) between baseline and 6 months. CONCLUSION:Intracoronary BMC therapy does not appear to exert any significant effects on the secretion of natriuretic peptides or inflammatory biomarkers in STEMI patients.
RCT Entities:
BACKGROUND: Intracoronary administration of autologous bone marrow stem cells (BMC) has been shown to result in a subtle improvement of global left ventricular ejection fraction after ST-elevation myocardial infarction (STEMI), but the overall benefits of BMC therapy are still unclear. We studied the influence of intracoronary injections of BMC on levels of natriuretic peptides and inflammatory mediators, which are well established prognostic biomarkers, in patients with STEMI. METHODS: In this randomized, double-blind study, consecutive patients with an acute STEMI treated with thrombolysis followed by PCI 2-6 days after STEMI, were randomly assigned to receive either intracoronary BMC or placebo medium into the infarct-related artery. Blood samples were drawn for biochemical determinations. RESULTS: From baseline to 6 months, there was a significant decrease in the levels of N-terminal probrain natriuretic peptide (NT-proBNP), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) in the whole patient population (P < 0.001 for all). However, no difference was observed between the BMC group (n = 39) and the placebo group (n = 39) in the change of the levels of NT-proANP (median -54 vs. +112 pmol/L), NT-proBNP (-88 vs. -115 pmol/L) or inflammatory markers IL-6 (-3.86 vs. -5.61 pg/mL), hsCRP (-20.29 vs. -22.36 mg/L) and tumor necrosis factor α (-0.12 vs. -0.80 pg/mL) between baseline and 6 months. CONCLUSION: Intracoronary BMC therapy does not appear to exert any significant effects on the secretion of natriuretic peptides or inflammatory biomarkers in STEMI patients.
Authors: Jozef Bartunek; Marc Vanderheyden; Bart Vandekerckhove; Samer Mansour; Bernard De Bruyne; Pieter De Bondt; Inge Van Haute; Nele Lootens; Guy Heyndrickx; William Wijns Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Juliana Jensen; Li-Ping Ma; Michael L X Fu; David Svaninger; Per-Arne Lundberg; Ola Hammarsten Journal: Clin Res Cardiol Date: 2010-03-13 Impact factor: 5.460
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: G Liuzzo; A Buffon; L M Biasucci; J R Gallimore; G Caligiuri; A Vitelli; S Altamura; G Ciliberto; A G Rebuzzi; F Crea; M B Pepys; A Maseri Journal: Circulation Date: 1998-12-01 Impact factor: 29.690
Authors: David M Leistner; Ulrich Fischer-Rasokat; Jörg Honold; Florian H Seeger; Volker Schächinger; Ralf Lehmann; Hans Martin; Iris Burck; Carmen Urbich; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus Journal: Clin Res Cardiol Date: 2011-06-03 Impact factor: 5.460
Authors: Roland Prondzinsky; Susanne Unverzagt; Henning Lemm; Nikolas-Arne Wegener; Axel Schlitt; Konstantin M Heinroth; Sebastian Dietz; Ute Buerke; Patrick Kellner; Harald Loppnow; Martin G Fiedler; Joachim Thiery; Karl Werdan; Michael Buerke Journal: Clin Res Cardiol Date: 2012-01-03 Impact factor: 5.460
Authors: Anita D Szady; Carl J Pepine; Shreela V Sharma; Christopher R Cogle; Emerson C Perin; Stephen G Ellis; Lemuel A Moyé Journal: Curr Atheroscler Rep Date: 2013-08 Impact factor: 5.113
Authors: Eva S Kehmeier; Wolfgang Lepper; Martina Kropp; Christian Heiss; Ulrike Hendgen-Cotta; Jan Balzer; Mirja Neizel; Christian Meyer; Marc W Merx; Pablo E Verde; Christian Ohmann; Gerd Heusch; Malte Kelm; Tienush Rassaf Journal: Clin Res Cardiol Date: 2012-05-06 Impact factor: 5.460